Development of a novel treatment for leukemia directed at tumor-associated mRNA splicing

Leukemia Research

Volumn 37, Issue 9, 2013, Pages 1125-1131

  Daines, Dayle A ^a   Sun, Jingping ^b   Uchakina, Olga N ^b   McKallip, Robert J ^b  

^a OLD DOMINION UNIVERSITY   (United States)

^b MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alternative splicing; Apoptosis; CD44 variant; CML

Indexed keywords

ANTINEOPLASTIC AGENT; CD44V ANTIGEN; CD44V6 ANTIGEN; CD44V8 ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; HUMANIZED FRAGMENT OF PSEUDOMONAS AERUGINOSA EXOTOXIN A; MESSENGER RNA; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A 24; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER GENE THERAPY; CELL STRAIN K 562; CELL VIABILITY; CONTROLLED STUDY; EXON; GENE PRODUCT; GENE TARGETING; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA CELL LINE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SECRETION; RNA SPLICING;

ALTERNATIVE SPLICING; APOPTOSIS; CD44 VARIANT; CML;

ADP RIBOSE TRANSFERASES; ANTIGENS, CD44; APOPTOSIS; BACTERIAL TOXINS; BLOTTING, WESTERN; CELL PROLIFERATION; EXOTOXINS; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; HUMANS; K562 CELLS; LEUKEMIA; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER; VIRULENCE FACTORS;

EID: 84880941723     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.06.017     Document Type: Article

References (26)

1. Magyarosy E., Sebestyen A., Timar J. Expression of metastasis associated proteins, CD44v6 and NM23-H1, in pediatric acute lymphoblastic leukemia. Anticancer Res 2001, 21(January-February (1B)):819-823.
2. Bendall L.J., Nilsson S.K., Khan N.I., James A., Bonnet C., Lock R.B., et al. Role of CD44 variant exon 6 in acute lymphoblastic leukaemia: association with altered bone marrow localisation and increased tumour burden. Leukemia 2004, 18(July (7)):1308-1311.
3. Nagel S., Hirschmann P., Dirnhofer S., Gunthert U., Tzankov A. Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas. Exp Hematol 2010, 38(January (1)):38-45.
4. Stauder R., Eisterer W., Thaler J., Gunthert U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 1995, 85(May (10)):2885-2899.
5. Liebisch P., Eppinger S., Schopflin C., Stehle G., Munzert G., Dohner H., et al. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Haematologica 2005, 90(April (4)):489-493.
6. Hertweck M.K., Erdfelder F., Kreuzer K.A. CD44 in hematological neoplasias. Ann Hematol 2011, 90(May (5)):493-508.
7. Gadhoum Z., Delaunay J., Maquarre E., Durand L., Lancereaux V., Qi J., et al. The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leuk Lymphoma 2004, 45(August (8)):1501-1510.
8. Charrad R.S., Gadhoum Z., Qi J., Glachant A., Allouche M., Jasmin C., et al. Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood 2002, 99(January (1)):290-299.
9. Riechelmann H., Sauter A., Golze W., Hanft G., Schroen C., Hoermann K., et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 2008, 44(September (9)):823-829.
10. Sauter A., Kloft C., Gronau S., Bogeschdorfer F., Erhardt T., Golze W., et al. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol 2007, 30(April (4)):927-935.
11. Colnot D.R., Roos J.C., de Bree R., Wilhelm A.J., Kummer J.A., Hanft G., et al. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2003, 52(September (9)):576-582.
12. Borjesson P.K., Postema E.J., Roos J.C., Colnot D.R., Marres H.A., van Schie M.H., et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2003, 9(September (10 Pt 2)):3961S-3972S.
13. Weldon J.E., Pastan I. A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 2011, 278(December (23)):4683-4700.
14. Iglewski B.H., Kabat D. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin. Proc Natl Acad Sci U S A 1975, 72(June (6)):2284-2288.
15. Iglewski B.H., Liu P.V., Kabat D. Mechanism of action of Pseudomonas aeruginosa exotoxin Aiadenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo. Infect Immun 1977, 15(January (1)):138-144.
16. Brinkman B.M. Splice variants as cancer biomarkers. Clin Biochem 2004, 37(July (7)):584-594.
17. Hayes G.M., Carpenito C., Davis P.D., Dougherty S.T., Dirks J.F., Dougherty G.J. Alternative splicing as a novel of means of regulating the expression of therapeutic genes. Cancer Gene Ther 2002, 9(February (2)):133-141.
18. Nakayama K., Pergolizzi R.G., Crystal R.G. Gene transfer-mediated pre-mRNA segmental trans-splicing as a strategy to deliver intracellular toxins for cancer therapy. Cancer Res 2005, 65(January (1)):254-263.
19. Gruber C., Gratz I.K., Murauer E.M., Mayr E., Koller U., Bruckner-Tuderman L., et al. Spliceosome-mediated RNA trans-splicing facilitates targeted delivery of suicide genes to cancer cells. Mol Cancer Ther 2011, 10(February (2)):233-241.
20. Onda M., Wang Q.C., Guo H.F., Cheung N.K., Pastan I. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res 2004, 64(February (4)):1419-1424.
21. Seth P., Brinkmann U., Schwartz G.N., Katayose D., Gress R., Pastan I., et al. Adenovirus-mediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and bone marrow purging. Cancer Res 1996, 56(March (6)):1346-1351.
22. Chen Y., Sun J., Lu Y., Tao C., Huang J., Zhang H., et al. Complexes containing cationic and anionic pH-sensitive liposomes: comparative study of factors influencing plasmid DNA gene delivery to tumors. Int J Nanomedicine 2013, 8:1573-1593.
23. Wang Y., Su H.H., Yang Y., Hu Y., Zhang L., Blancafort P., et al. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther 2013, 21(February (2)):358-367.
24. Zhao X.Y., Nie C.L., Liang S.F., Yuan Z., Deng H.X., Wei Y.Q. Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1. Biomed Pharmacother 2012, 66(December (8)):597-602.
25. Kim R., Minami K., Nishimoto N., Toge T. Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer. Int J Oncol 2001, 18(February (2)):363-367.
26. Jijiwa M., Demir H., Gupta S., Leung C., Joshi K., Orozco N., et al. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS ONE 2011, 6(9):e24217.